Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables: 2013-2019

Historic Receivables for Theravance Biopharma (TBPH) over the last 6 years, with Sep 2019 value amounting to $20.1 million.

  • Theravance Biopharma's Receivables rose 189.81% to $20.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $58.8 million, marking a year-over-year increase of 107.00%. This contributed to the annual value of $10.7 million for FY2018, which is 14.00% up from last year.
  • Theravance Biopharma's Receivables amounted to $20.1 million in Q3 2019, which was down 0.12% from $20.1 million recorded in Q2 2019.
  • In the past 5 years, Theravance Biopharma's Receivables ranged from a high of $39.1 million in Q1 2016 and a low of $4.8 million during Q1 2018.
  • Its 3-year average for Receivables is $10.5 million, with a median of $8.9 million in 2017.
  • In the last 5 years, Theravance Biopharma's Receivables soared by 674,066.67% in 2015 and then tumbled by 81.96% in 2017.
  • Over the past 5 years, Theravance Biopharma's Receivables (Quarterly) stood at $37.2 million in 2015, then slumped by 73.83% to $9.7 million in 2016, then fell by 3.70% to $9.4 million in 2017, then rose by 14.00% to $10.7 million in 2018, then skyrocketed by 189.81% to $20.1 million in 2019.
  • Its last three reported values are $20.1 million in Q3 2019, $20.1 million for Q2 2019, and $7.9 million during Q1 2019.